Biogen (HAM:IDP) Net Change in Cash

: €1,159 Mil (TTM As of Mar. 2023)

View and export this data going back to 2001. Start your Free Trial

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Biogen's Net Change in Cash for the three months ended in Mar. 2023 was €-487 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2023 was €1,159 Mil.

Biogen Net Change in Cash Historical Data

The historical data trend for Biogen's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Net Change in Cash

-306.95

1,520.19

-1,300.81

823.23

1,093.06

Biogen Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Net Change in Cash																-464.99	848.85	1,039.29	-241.95	-486.71

Biogen Net Change in Cash Calculation

Biogen's Net Change in Cash for the fiscal year that ended in Dec. 2022 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	1306.779	+	1488.31	+	-1649.451	+	-52.581
	=	1,093

Biogen's Net Change in Cash for the quarter that ended in Mar. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 425.25 + -890.102 + -40.536 + 18.68

= -487

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,159 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Biogen's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (HAM:IDP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (HAM:IDP) » Definitions » Net Change in Cash

Comparable Companies

NAS:HZNP NYSE:OGN NAS:SCLX NAS:AMRN NAS:GILD NAS:AMGN NYSE:BMY NYSE:PFE NYSE:LLY NYSE:JNJ NYSE:MRK XSWX:ROG NYSE:ABBV LSE:AZN XSWX:NOVN XPAR:SAN LSE:GSK TSE:4568 XTER:BAYN TSE:4519

Traded in Other Exchanges

BIIB:USA BIIB:Mexico IDP:Germany BIIB34:Brazil BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

http://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (HAM:IDP) Headlines

No Headlines